CA2603325A1 - Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders - Google Patents

Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders Download PDF

Info

Publication number
CA2603325A1
CA2603325A1 CA002603325A CA2603325A CA2603325A1 CA 2603325 A1 CA2603325 A1 CA 2603325A1 CA 002603325 A CA002603325 A CA 002603325A CA 2603325 A CA2603325 A CA 2603325A CA 2603325 A1 CA2603325 A1 CA 2603325A1
Authority
CA
Canada
Prior art keywords
tnf
raav
tnfr
mammal
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002603325A
Other languages
English (en)
French (fr)
Inventor
Haim Burstein
William V. Giannobile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ampliphi Biosciences Corp
Original Assignee
Targeted Genetics Corporation
Haim Burstein
William V. Giannobile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Genetics Corporation, Haim Burstein, William V. Giannobile filed Critical Targeted Genetics Corporation
Publication of CA2603325A1 publication Critical patent/CA2603325A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
CA002603325A 2005-03-31 2006-03-31 Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders Abandoned CA2603325A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66738805P 2005-03-31 2005-03-31
US60/667,388 2005-03-31
PCT/US2006/011764 WO2006105344A2 (en) 2005-03-31 2006-03-31 Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders

Publications (1)

Publication Number Publication Date
CA2603325A1 true CA2603325A1 (en) 2006-10-05

Family

ID=37054152

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002603325A Abandoned CA2603325A1 (en) 2005-03-31 2006-03-31 Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders

Country Status (5)

Country Link
EP (1) EP1871799A2 (ja)
JP (1) JP2008536826A (ja)
AU (1) AU2006230419A1 (ja)
CA (1) CA2603325A1 (ja)
WO (1) WO2006105344A2 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2623978A1 (en) * 2012-02-03 2013-08-07 Charité - Universitätsmedizin Berlin CD8+ T-cell subsets as markers for prediction of delayed fracture healing
NZ629309A (en) * 2012-02-22 2016-03-31 Nvip Pty Ltd Tumour necrosis factor receptor fusion proteins and methods of using the same
IL302282A (en) * 2020-10-29 2023-06-01 Regenxbio Inc Vectored TNF-alpha antagonists for ocular indications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
CA2374597A1 (en) * 1999-05-28 2000-12-07 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
EP1450837A4 (en) * 2001-08-07 2006-01-04 Immunex Corp INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES
KR20050042466A (ko) * 2002-07-19 2005-05-09 애보트 바이오테크놀로지 리미티드 ＴＮＦα 관련 질환의 치료

Also Published As

Publication number Publication date
WO2006105344A2 (en) 2006-10-05
EP1871799A2 (en) 2008-01-02
WO2006105344A3 (en) 2007-01-11
AU2006230419A1 (en) 2006-10-05
JP2008536826A (ja) 2008-09-11

Similar Documents

Publication Publication Date Title
EP1180159B1 (en) Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders
CA2379166C (en) Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
RU2683497C2 (ru) Композиция и способы высокоэффективного переноса генов с помощью вариантов капсида aav
JP2005516949A (ja) Ｇｄｎｆの骨格筋へのアデノ随伴ウイルス媒介性のデリバリー
CN104470945A (zh) 高转导效率的rAAV载体、组合物及其使用方法
WO2004027019A2 (en) Improved raav expression systems for genetic modification of specific capsid proteins
WO2015124546A1 (en) Aav vectors for the treatment of ischemic and non-ischemic heart disease
JP2021510528A (ja) 遺伝子治療のための修飾ｒＡＡＶキャプシドタンパク質
CN111936172A (zh) 用于治疗视网膜病症的组合物和方法
CA2603325A1 (en) Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders
EP1618201A1 (en) Vp2 - modified raav vectors and uses thereof
EP1939300A1 (en) Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
AU2005202946B2 (en) Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
EP1916258A2 (en) Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
AU2008207383A1 (en) Enhancement of expression of a single-stranded heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs

Legal Events

Date Code Title Description
FZDE Dead